全文获取类型
收费全文 | 1491篇 |
免费 | 116篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 37篇 |
妇产科学 | 41篇 |
基础医学 | 150篇 |
口腔科学 | 13篇 |
临床医学 | 164篇 |
内科学 | 400篇 |
皮肤病学 | 8篇 |
神经病学 | 80篇 |
特种医学 | 51篇 |
外科学 | 161篇 |
综合类 | 45篇 |
预防医学 | 102篇 |
眼科学 | 207篇 |
药学 | 87篇 |
肿瘤学 | 58篇 |
出版年
2021年 | 14篇 |
2020年 | 9篇 |
2019年 | 18篇 |
2018年 | 14篇 |
2017年 | 19篇 |
2016年 | 23篇 |
2015年 | 20篇 |
2014年 | 36篇 |
2013年 | 53篇 |
2012年 | 74篇 |
2011年 | 72篇 |
2010年 | 38篇 |
2009年 | 28篇 |
2008年 | 78篇 |
2007年 | 79篇 |
2006年 | 80篇 |
2005年 | 65篇 |
2004年 | 67篇 |
2003年 | 62篇 |
2002年 | 55篇 |
2001年 | 48篇 |
2000年 | 56篇 |
1999年 | 48篇 |
1998年 | 12篇 |
1997年 | 11篇 |
1996年 | 19篇 |
1995年 | 12篇 |
1994年 | 19篇 |
1993年 | 11篇 |
1992年 | 43篇 |
1991年 | 46篇 |
1990年 | 35篇 |
1989年 | 28篇 |
1988年 | 46篇 |
1987年 | 30篇 |
1986年 | 17篇 |
1985年 | 24篇 |
1984年 | 19篇 |
1983年 | 14篇 |
1982年 | 12篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1979年 | 11篇 |
1978年 | 10篇 |
1977年 | 11篇 |
1976年 | 7篇 |
1974年 | 13篇 |
1973年 | 11篇 |
1972年 | 10篇 |
1971年 | 8篇 |
排序方式: 共有1613条查询结果,搜索用时 15 毫秒
151.
Morphine, the recommended drug for the management of moderate to severe cancer pain, is metabolized predominantly to the glucuronides morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G). The quantitative clinical importance of these metabolites following the administration of oral morphine is unclear. This study investigates the relationship between plasma concentrations of morphine (M), M6G, M3G and clinical effects in patients receiving sustained release oral morphine for cancer-related pain. Peak and trough plasma concentrations of morphine and its metabolites were determined by high-performance liquid chromatography (HPLC). At corresponding time points, pain [Visual Analogue Scales (VAS), Verbal Rating Scales (VRS), Pain Relief Scores (PRS)] and toxicity (VAS and VRS) were assessed. Renal and liver function tests were performed. Forty-six patients were included in the study. There was a significant correlation between dose and both peak and trough plasma M, M6G and M3G (r > 0.60, P < 0.001 for each). Differences between peak and trough M, M6G, M3G, M+M6G, M6G:M, M3G:M and M3G:M6G were all significant (P < 0.001 for each). Pain was generally well controlled in the group, with a median VAS of 15 mm at the peak blood sampling time point. The differences between peak and trough values for VAS pain, VAS nausea and VAS drowsiness were not statistically significant (P = 0.078, 0.45 and 0.099, respectively). There were no differences in peak or trough morphine and metabolite concentrations or ratios between patients with low (< median) or high pain scores. Similarly, there was no significant relationship between high and low plasma concentrations and clinical effect. This study did not identify a simple relationship between plasma concentrations of morphine, morphine metabolites or metabolite ratios and clinical effects in patients with cancer and pain who were receiving chronic oral morphine therapy. Although overall pain control was good, there was marked interpatient variability in the dose of morphine and the plasma concentrations necessary to achieve this degree of analgesia. 相似文献
152.
E M Quigley 《The Quarterly journal of medicine》1987,65(246):799-810
The study of small intestinal motor activity has certainly emerged from relative obscurity to a position where it may indeed become an important clinical tool. Modern technology has led to a considerable increase in our understanding of the physiology of motor function and has brought us to a stage where small intestinal motility is amenable to study in man. It is clear that coordinated motor function of the small intestine is central to integrated digestive function. Normal patterns, and in particular normal variants, are still being defined, and both the investigator and the clinician need to be particularly aware of interspecies, intersubject and interregional variations. While in some instances, abnormal motility is clearly related to an underlying disorder of intestinal neuromuscular function, in others, and in particular in functional gastrointestinal disorders, the overall experience of intestinal motility recordings in man is still too limited to allow us to declare with confidence whether reported abnormalities are, indeed, truly aberrant patterns or whether they are causally related to a given patient's symptoms. 相似文献
153.
Santosh L. Saraf Annie L. Oh Pritesh R. Patel Karen Sweiss Matthew Koshy Sally Campbell-Lee Michel Gowhari Shivi Jain David Peace John G. Quigley Irum Khan Robert E. Molokie Nadim Mahmud Victor R. Gordeuk Damiano Rondelli 《Biology of blood and marrow transplantation》2018,24(8):1759-1765
We report on the screening and development of haploidentical hematopoietic stem cell transplantation (HSCT) for adult patients with clinically aggressive sickle cell disease (SCD) at our institution. Of 50 adult SCD patients referred for HSCT between January 2014 and March 2017, 20% were denied by insurance. Of 41 patients initially screened, 10% lacked an available haploidentical donor, 29% had elevated donor-specific antibodies (DSAs), and 34% declined to proceed to HSCT. All 10 patients who were transplanted received peripheral blood stem cells. The initial 2 were conditioned with alemtuzumab/total body irradiation (TBI) 3?Gy followed by post-transplant cyclophosphamide and failed to engraft. The next 8 patients received the regimen developed at Johns Hopkins University with TBI 3?Gy. Granulocyte colony-stimulating factor was administered from day +12 in those with HbS < 30%. All 8 patients engrafted with a median time to neutrophil >.5 × 109/L of 22 days (range, 18 to 23). One patient subsequently lost the graft, and 7 (87.5%) maintained >95% donor cell chimerism at 1-year post-HSCT. Two patients developed acute graft-versus-host disease (GVHD) of at least grade II. One had chronic GVHD and died >1 year after HSCT of unknown causes. With a median follow-up of 16 months (range, 11 to 29), 7 patients (87.5%) are alive. Our findings suggest that limited insurance coverage, high rate of DSAs, and patient declining HSCT may limit the availability of haploidentical HSCT in adult SCD patients. The modified Hopkins regimen used here demonstrates high engraftment and low morbidity rates and should be tested in larger, multicenter, prospective clinical trials. 相似文献
154.
Irritable bowel syndrome affects approximately 10-15% of the European population, although prevalence rates vary depending on the classification used and the country surveyed. This may be due to differences in patterns of medical care and diagnosis of the condition. Up to 70% of individuals with irritable bowel syndrome may not have been formally diagnosed. The disorder affects 1.5-3 times as many women as men and poses a significant economic burden in Europe, estimated at euro 700-euro 1600 per person per year. It also reduces quality of life and is associated with psychological distress, disturbed work and sleep, and sexual dysfunction. It is a chronic disorder, which affects many individuals for more than 10 years. Most patients are managed in primary care, although some are referred to gastroenterologists and other specialists. Patients with irritable bowel syndrome undergo more abdomino-pelvic surgery than the general population. We propose that a positive diagnosis of the condition may avoid the delay in diagnosis many patients experience. We conclude that, in Europe, there are significant unmet needs including lack of familiarity with irritable bowel syndrome, difficulties in diagnosis and lack of effective treatments for the multiple symptoms of the disorder. The development of pan-European guidelines for irritable bowel syndrome will benefit patients with this condition in Europe. 相似文献
155.
156.
Caroline Codling Liam O’Mahony Fergus Shanahan Eamonn M. M. Quigley Julian R. Marchesi 《Digestive diseases and sciences》2010,55(2):392-397
Purpose
The objectives of this study were, firstly, to determine the diversity of the host’s gut microbiota in irritable bowel syndrome (IBS) using a culture-independent method (DGGE of the 16S rRNA gene) and, secondly, to examine mucosal biopsies of IBS patients and compare them to their own fecal microbiota. 相似文献157.
Despite the current increase in interest in the role of the microbiota in health and disease and the recognition, for over 50 years, that an excess of colonic-type flora in the small intestine could lead to a malabsorption syndrome, small intestinal overgrowth remains poorly defined. This lack of clarity owes much to the difficulties that arise in attempting to arrive at consensus with regard to the diagnosis of this condition: there is currently no gold standard and the commonly available methodologies (the culture of jejunal aspirates and a variety of breath tests) suffer from considerable variations in their performance and interpretation, leading to variations in the prevalence of overgrowth in a variety of clinical contexts. Treatment is similarly supported by a scant evidence base and the most commonly used antibiotic regimens owe more to custom than clinical trials. 相似文献
158.
159.
160.
Hannon MJ Dinneen S Yousif O Thompson CJ Quigley EM O'Halloran DJ 《Irish medical journal》2011,104(5):135-137
The management of diabetic gastroparesis resistant to medical therapy is very difficult Gastric electrical stimulation (GES) is a relatively new therapeutic modality which has shown some promise in international trials. It has seen use in four patients in Ireland. Our aim was to determine if GES improved patients' outcomes in terms of duration and cost of inpatient stay and glycaemic control. We reviewed the patients' case notes and calculated the number of days spent as an inpatient with symptomatic gastroparesis pre and post pacemaker, the total cost of these admissions, and patients' average HbA1c pre and post GES. Mean length of stay in the year pre GES was 81.75 days and 62.25 days in the year post GES (p=0.89). There was also no improvement in glycaemic control following GES. GES has been ineffective in improving length of inpatient stay and glycaemic control in our small patient cohort. 相似文献